| scholarly article | Q13442814 |
| P356 | DOI | 10.1006/BBRC.1999.1693 |
| P698 | PubMed publication ID | 10558893 |
| P50 | author | Sebastian Kügler | Q71012165 |
| P2093 | author name string | Bähr M | |
| Isenmann S | |||
| Weller M | |||
| Dichgans J | |||
| Ashkenazi A | |||
| Roth W | |||
| Naumann U | |||
| P2860 | cites work | Lethal effect of the anti-Fas antibody in mice | Q36696599 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neurotoxicity | Q3338704 |
| xenograft | Q64148587 | ||
| P304 | page(s) | 479-483 | |
| P577 | publication date | 1999-11-01 | |
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity | |
| P478 | volume | 265 |
| Q47549547 | A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma |
| Q40023794 | A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis |
| Q38710179 | A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis |
| Q34090695 | APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis |
| Q39392672 | AW00179 potentiates TRAIL-mediated death of human lung cancer H1299 cells through ROS-JNK-c-Jun-mediated up-regulation of DR5 and down-regulation of anti-apoptotic molecules |
| Q37269047 | Activation of autophagy flux by metformin downregulates cellular FLICE-like inhibitory protein and enhances TRAIL- induced apoptosis |
| Q40605148 | Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma |
| Q37086965 | Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme |
| Q37425788 | Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells |
| Q40362040 | Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand |
| Q37219397 | Apigenin Sensitizes Huh-7 Human Hepatocellular Carcinoma Cells to TRAIL-induced Apoptosis |
| Q34532325 | Apo2L/TRAIL and its death and decoy receptors |
| Q39874761 | Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma |
| Q39790634 | Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer |
| Q36021584 | Apoptosis in gliomas: molecular mechanisms and therapeutic implications |
| Q57384572 | Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects |
| Q36017772 | Apoptosis-based therapies and drug targets |
| Q39956386 | Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins |
| Q55475811 | Bag-1 and Bcl-2 gene transfer in malignant glioma: modulation of cell cycle regulation and apoptosis. |
| Q45883318 | Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth |
| Q33923323 | Brain ischemia and reperfusion: molecular mechanisms of neuronal injury |
| Q43682296 | CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release |
| Q39771092 | Calmodulin inhibition contributes to sensitize TRAIL-induced apoptosis in human lung cancer H1299 cells |
| Q40367155 | Cancer gene therapy using a novel secretable trimeric TRAIL. |
| Q40446642 | Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner |
| Q35665706 | Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. |
| Q40025662 | Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells |
| Q38869957 | Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas |
| Q38960128 | Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors |
| Q33646687 | Cord Blood Stem Cell-Mediated Induction of Apoptosis in Glioma Downregulates X-Linked Inhibitor of Apoptosis Protein (XIAP) |
| Q73704158 | Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions |
| Q43902939 | Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells |
| Q37515926 | Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. |
| Q37319386 | Directing cancer cells to self-destruct with pro-apoptotic receptor agonists |
| Q39374254 | Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells |
| Q39811470 | Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells |
| Q35006015 | Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts |
| Q58690946 | EfficientIn VitroTRAIL-Gene Delivery in Drug-Resistant A2780/DDP Ovarian Cancer Cell Line via Magnetofection |
| Q39983073 | Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. |
| Q40490888 | Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells |
| Q28609079 | FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2 |
| Q34966112 | Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells |
| Q44420163 | HSV-1 VP22 augments adenoviral gene transfer to CNS neurons in the retina and striatum in vivo |
| Q35670756 | Heterogeneity of primary glioblastoma cells in the expression of caspase-8 and the response to TRAIL-induced apoptosis |
| Q57623656 | Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) |
| Q38921239 | Icaritin Sensitizes Human Glioblastoma Cells to TRAIL-Induced Apoptosis |
| Q36708286 | Immunomodulatory neural stem cells for brain tumour therapy |
| Q55473819 | Induction of TRAIL-mediated glioma cell death by human T cells. |
| Q40560848 | Induction of potent TRAIL-mediated tumoricidal activity by hFLEX/Furin/TRAIL recombinant DNA construct |
| Q39905584 | Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2. |
| Q54020370 | Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. |
| Q38827688 | Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5. |
| Q35440540 | Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. |
| Q40286281 | Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. |
| Q38115574 | Manipulating the apoptotic pathway: potential therapeutics for cancer patients |
| Q40094198 | Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. |
| Q34590759 | Mechanisms of apoptosis in central nervous system tumors: application to theory |
| Q44757357 | N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines |
| Q44559483 | NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells |
| Q40661645 | Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity |
| Q39411406 | Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1. |
| Q35594029 | Novel chemotherapeutic agents for the treatment of glioblastoma multiforme |
| Q36285964 | On the TRAIL of a new therapy for leukemia. |
| Q35006422 | PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy |
| Q38807560 | Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer |
| Q39495654 | Pool-specific regulation of motor neuron survival by neurotrophic support. |
| Q64376217 | Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein |
| Q35756907 | Potential for TRAIL as a therapeutic agent in ovarian cancer |
| Q33180363 | Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer |
| Q44550507 | Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling |
| Q39923672 | Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells |
| Q40125508 | Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors |
| Q40599197 | Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. |
| Q40494567 | Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. |
| Q46326788 | Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors |
| Q28537942 | Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines |
| Q24290219 | Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells |
| Q44644550 | Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells |
| Q38865185 | Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin |
| Q40472879 | Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speci |
| Q48548442 | Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo |
| Q40318203 | Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors |
| Q37761935 | Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics |
| Q36546689 | TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo |
| Q35756919 | TRAIL and malignant glioma. |
| Q39978504 | Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells |
| Q34791120 | Targeting death and decoy receptors of the tumour-necrosis factor superfamily |
| Q38677019 | Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma |
| Q37356520 | Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide |
| Q42479312 | Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein |
| Q35172090 | The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases |
| Q40295172 | The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumors |
| Q41978994 | The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer |
| Q39691784 | Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma |
| Q36508944 | Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. |
| Q34272896 | Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells |
| Q43903493 | Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. |
| Q34097241 | mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells |
Search more.